Accueil・Liste d'Actions・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

48.37 -1.31

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

48.46

Max

49.68

Chiffres clés
By Trading Economics
Revenu	-56M -58M
Ventes	11M 219M
BPA	0.39
Marge bénéficiaire	-26.646
Employés	778
EBITDA	-50M -30M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+32.98% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	79M 2.8B
Ouverture précédente	49.68
Clôture précédente	48.37

Sentiment de l'Actualité

By Acuity

75%

25%

316 / 340 Classement par Healthcare

Supernus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 août 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17 août 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14 août 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 août 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 août 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 août 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 août 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 août 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 août 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 août 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 août 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 août 2026, 19:51 UTC

Social Media

News

Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 juil. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 juil. 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

29 juil. 2026, 17:26 UTC

Supernus Pharmaceuticals Inc. shares are lower today amid volatility, with no specific news identified. The stock remains below its 20-day moving average.

28 juil. 2026, 17:06 UTC

Supernus Pharmaceuticals Inc. shares are higher today, recovering from an earlier decline. The stock remains near the lower end of its one-month trading range.

27 juil. 2026, 20:06 UTC

Supernus Pharmaceuticals Inc shares are higher Monday, despite earlier gains pulling back. Market dynamics reflect a significant decline in oil prices and inflation reassessment.

24 juil. 2026, 19:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, following an early peak, amid broader market dynamics influenced by a pullback in crude oil prices.

20 juil. 2026, 20:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early high amid a broader market decline during the session.

Comparaison

Variation de prix

Supernus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

32.98% hausse

Prévisions sur 12 Mois

Moyen 65.2 USD 32.98%

Haut 67 USD

Bas 63 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

316 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.